Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 08/26/24
Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)GlobeNewsWire • 07/28/24
Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 07/19/24
Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 07/18/24
Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's DiseaseGlobeNewsWire • 07/10/24
Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of DirectorsGlobeNewsWire • 07/08/24
Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise TransactionGlobeNewsWire • 06/18/24
Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024GlobeNewsWire • 06/17/24
Longeveron® Announces Contract Development and Manufacturing Business and First ContractGlobeNewsWire • 06/03/24
Longeveron Announces First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/14/24